Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma
Abstract The limited benefits of immunotherapy against glioblastoma (GBM) is closely related to the paucity of T cells in brain…
CNS cancer
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma
Abstract Background: Preclinical data suggest some cannabinoids may exert antitumour effects against glioblastoma (GBM). Safety and preliminary efficacy of nabiximols…
Secretome analysis of patient-derived GBM tumor spheres identifies midkine as a potent therapeutic target
Abstract Glioblastoma (GBM) is the most lethal primary brain tumor with few treatment options. The survival of glioma-initiating cells (GICs)…